The impact of genomic and proteomic technologies on the development of new cancer drugs

Annals of Oncology

Volumn 13, Issue SUPPL. 4, 2002, Pages 115-124

  Workman, P ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; ANTINEOPLASTIC AGENT; CETUXIMAB; CI 10 40; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; FLAVOPIRIDOL; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; IMATINIB; LEPTOMYCIN B; LONAFARNIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; ONYX 015; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEASOME INHIBITOR; PROTEIN P53; RAF PROTEIN; RAPAMYCIN DERIVATIVE; RAS PROTEIN; ROSCOVITINE; SORAFENIB; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER GENETICS; CANCER RESEARCH; CONTROLLED STUDY; DNA MICROARRAY; DRUG TARGETING; GENE EXPRESSION; GENE SEQUENCE; GENOMICS; HUMAN; PRIORITY JOURNAL; PROTEOMICS; SIDE EFFECT; SUICIDE GENE THERAPY;

EID: 0036436036     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf648     Document Type: Article

References (62)

1. Workman P, Kaye SB. A Trends Guide to Cancer Therapeutics. Trends Mol Med 2002; 8 (Suppl.): S1-S9.
2. Workman P, Kaye SB. Translating basic cancer research into new cancer therapeutics. Trends Mol Med 2002; 8 (Suppl.): S27-S31.
3. Workman P. Scoring a bull's-eye against cancer genome targets. Curr Opin Pharmacol 2001; 1: 342-352.
4. Workman P. Changing times: Developing cancer drugs in genome-land. Curr Opin Invest Drugs 2001; 2: 1128-1135.
5. Garrett MD, Workman P. Millennium review. Discovering novel chemotherapeutic drugs in the third millennium. Eur J Cancer 1999; 35: 2010-2030.
6. International Human Genome Sequencing Consortium, Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921.
7. Ventner JC, Adams MD, Myers EW et al. The sequence of the human genome. Science 2001; 291: 1304-1351.
8. Brent R. Genomic biology. Cell 2000; 100: 169-183.
9. Jiminez-Sanchez G, Childs B, Valle D. Human disease genes. Nature 2001; 409: 853-855.
10. Baltimore D. Our genome unveiled. Nature 2001; 409: 814-815.
11. The human genome, in proportion (Editorial). Lancet 2001; 357: 489.
12. A cold dose of medicine (Editorial). Nature Biotechnol 2001; 19: 181.
13. All hands on deck (Editorial). Nature Genet 2001; 27: 347-349.
14. Davies K. The sequence: inside the race for the human genome. London: Weidenfield and Nicholson 2001.
15. Sulston J, Ferry G. The Common Thread: a Story of Science, Politics, Ethics and the Human Sequence. London: Bantam Press 2001.
16. Sanger F, Air GM, Barrell BG et al. Nucleotide sequence of bacterio-phage φX174. Nature 1977; 265: 687-695.
17. Prober JM, Trainor GL, Dam RJ et al. A system for rapid DNA sequencing with fluorescent chain-terminating dideoxynucleotides. Science 1987; 238: 333-341.
18. Watson JP, Crick FHC. A structure for deoxyribose nucleic acid. Nature 1953; 171: 737-738.
19. Watson JP, Crick FHC. Genetical implications of the structure of deoxyribonucleic acid. Nature 1953; 171: 964-967.
20. Watson JP. The Double Helix. New York, NY: Weidenfield and Nicholson 1968, Penguin, Harmondsworth paperback edition, 1970. See also the Norton Critical Edition, edited by Gunther Stent, Norton, New York and London, 1980.
21. Judson FH. The Eighth Day of Creation. London: Jonathan Cape 1979; paperback edition: Penguin, Harmondsworth 1995.
22. Claverie JM. What if there are only 30 000 human genes? Science 2001; 291: 1255-1527.
23. Sorek R, Amitai M. Piecing together the significance of splice. Nature Biotechnol 1996; 19: 196.
24. Golub TR. Genome-wide views of cancer. N Engl J Med 2001; 344: 601-602.
25. Weinstein JN. Fishing expeditions. Science 1998; 282: 627.
26. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001; 411: 342-348.
27. Hanahan D, Weinberg A. The hallmarks of cancer. Cell 2000; 100: 57-70.
28. Ponder BAG. Cancer genetics. Nature 2001; 411: 336-341.
29. Vogelstein B, Kinzler K. The multistep nature of cancer. Trends Genet 1993; 9: 138-141.
30. Weinberg RA (ed.). Oncogenes and the molecular origins of cancer. Cold Spring Harbour, NY: Cold Spring Harbour Press 1989.
31. Wooster R, Bignell G, Lancaster J et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789-792.
32. Papadopoulos N, Nicolaides NC, Wei YF et al. Mutation of a mutL homolog in hereditary colon cancer. Science 1994; 263: 1625-1629.
33. Futreal PA, Ksprzyk A, Birney E et al. Cancer and genomics. Nature 2001; 409: 850-855.
34. Stratton M. The cancer genome project: systematic searches for mutations in human cancer. Br J Cancer 2001; 85 (Suppl. 1): (Abstr S1).
35. Ratain MJ, Relling MV. Gazing into a crystal ball-cancer therapy in the post-genome era. Nature Med 2001; 7: 283-285.
36. Gelmon KA, Eisenhauer EA, Harris AL et al. Anticancer agents targeting signalling molecules and cancer cell environment: challenges for drug development. J Natl Cancer Inst 1999; 19: 1281-1287.
37. Druker BJ. ST1571 (GleeveC™) as a paradigm for cancer therapy. Trends Mol Med 2002; 8 (Suppl.): S14-S18.
38. de Bono JS, Rowinsky EK. The ErbB receptor family: a therapeutic target cancer. Trends Mol Med 2002; 8 (Suppl.): S19-S26.
39. Herrara R, Sebolt-Leopold JS. Unravelling the complexities of the Raf/MAP kinase pathway for pharmacological intervention. Trends Mol Med 2002; 8 (Suppl.): S27-S31.
40. Lane DP, Lain S. Therapeutic exploitation of the p53 pathway. Trends Mol Med 2002; 8 (Suppl.): S38.
41. Sausville EA. Complexities in the development of cyclin-dependant kinase-inhibitor drugs. Trends Mol Med 2002; 8 (Suppl.): S32-S37.
42. Brown A, Strathdee G. Epigenomics and epigenetic therapy of cancer. Trends Mol Med 2002; 8 (Suppl.): S43-S48.
43. Kouzarides T. Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev 1999; 9: 40-48.
44. Strahl D, Allis CD. The language of histone modifications. Nature 2000; 403: 41-45.
45. Adams J. Proteasome inhibition: a novel approach to cancer therapy. Trends Mol Med 2002; 8 (Suppl.): S49-S54.
46. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 2002; 8 (Suppl.): S55-S60.
47. Maloney A, Workman P. Hsp90 as a new therapeutic target for cancer therapy. Exp Opin Biol Ther 2002; 2: 3-24.
48. Semenza GL. HIF-1 and tumour progression: pathophysiology and therapeutics. Trends Mol Med 2002; 8 (Suppl.): S62-S67.
49. Kirn D, Niculescu-Duvaz I, Hallden G, Springer CJ. The emerging fields of suicide gene therapy and virotherapy. Trends Mol Med 2002; 8 (Suppl.): S68-S73.
50. Velculescu VE, Zhang L, Volgestein B, Kinzler KW. Serial analysis of gene expression. Science 1995; 270: 484-487.
51. Lockhart DJ, Winzelar EA. Genomics, gene expression and DNA arrays. Nature 2000; 405: 827-836.
52. Debouck C, Goodfellow PN. DNA microarrays in drug discovery and development. Nature Genet 1999; 21: 48-51.
53. Stratowa C, Wilgenbus KK. Gene expression profiling in drug discovery. Curr Opin Mol Ther 1999; 1: 671-679.
54. Clarke PA, te Poele R, Wooster R, Workman P. Gene expression microarray analysis in cancer biology, pharmacology and drug development: progress and potential. Biochem Pharmacol 2001; 62: 1311-1336
55. Perou CM, Serlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
56. Golub TR, Slonim DK, Tamayo P et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999; 286: 531-537.
57. Scherf U, Ross DT, Waltham M et al. A gene expression database for the molecular pharmacology of cancer. Nature Genet 2000; 24: 227-235.
58. Clarke PA, Hostein I, Banerji U et al. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the Hsp90 molecular chaperone. Oncogene 2000; 19: 4125-4133.
59. Knudsen S. A Biologists Guide to Analysis of DNA Microarray Data. New York, NY: Wiley 2002.
60. Blackstock W, Mann M (eds). Proteomics: A Trends Guide. London: Elsevier Science 2000.
61. Blohm D, Guiseppi-Elie A. New developments in microarray technology. Curr Opin Biotechnol 2001; 12: 41-47.
62. van Berkum NL, Holstege FCP. DNA microarrays: Raising the profile. Curr Opin Biotechnol 2001; 12: 48-52.